on ABIVAX (EPA:ABVX)
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
Abivax, a clinical-stage biotechnology company, will present three scientific abstracts on its lead drug candidate, obefazimod, at the UEG Week 2024 in Vienna. The presentations will take place from October 12-15, 2024.
Professor Bruce E. Sands will deliver an oral presentation on the Phase 2b efficacy and safety data at weeks 48 and 96 for obefazimod-treated patients with moderately to severely active ulcerative colitis (UC). The study focuses on non-responders at week 8 of the induction phase.
Two moderated poster presentations will discuss corticosteroid-free efficacy and safety data of obefazimod at weeks 48 and 96, and the impact of obefazimod induction therapy on combined histologic and endoscopic outcomes at week 8 in UC patients.
Abivax aims to advance the treatment paradigm for UC with obefazimod, a once-daily oral therapy. The company's Chief Medical Officer, Fabio Cataldi, MD, highlighted the potential of obefazimod in enhancing UC treatment.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABIVAX news